Thus, the aim of the present paper is the assessment of the influence of the long-acting insulin analogue, i.e., insulin detemir, on the expression of the mentioned proteins in the blood of obese individuals with type 2 diabetes both before the treatment, as well as after six months of therapy with the mentioned, long-acting insulin analogue. The gene discussed is INS; the disease is type 2 diabetes mellitus.